Performance of 4 methods for screening of latent tuberculosis infection in patients with chronic inflammatory arthritis under TNFα inhibitors: a 24-month prospective study

• Published in: Advances in rheumatology (London, England) Vol. 61; no. 1; p. 71
• Main Authors: Gomes, Carina M F, Terreri, Maria Teresa, Moraes-Pinto, Maria Isabel, Pinheiro, Marcelo M
• Format: Journal Article
• Language: English
• Published: England Sociedade Brasileira de Reumatologia 27-11-2021; BMC
• Subjects: Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Chronic inflammatory arthritis; Humans; IGRAs; Latent Tuberculosis - diagnosis; Latent tuberculosis infection; Non-interventional trial; Prospective cohort; Prospective Studies; RHEUMATOLOGY; TNFα inhibitors; Tuberculin Test; Tumor Necrosis Factor-alpha; IGRAs; Chronic inflammatory arthritis; Non-interventional trial; Latent tuberculosis infection; TNFα inhibitors; Prospective cohort
• ISSN: 2523-3106; 2523-3106
• DOI: 10.1186/s42358-021-00226-z

The reactivation rate of tuberculosis in patients with chronic inflammatory arthritis (CIA) on TNFα inhibitors (TNFi) and baseline negative screening for latent tuberculosis infection (LTBI) is higher than in the general population.
To compare the performance of tuberculin skin test (TST), TST-Booster, ELISPOT (T-SPOT.TB) and QuantiFERON-TB Gold in tube (QFT-IT) to detect LTBI in patients with CIA on TNFi.
A total of 102 patients with CIA [rheumatoid arthritis (RA), n = 40; ankylosing spondylitis (AS), n = 35; psoriatic arthritis (PsA), n = 7; and juvenile idiopathic arthritis (JIA), n = 20] were prospectively followed-up for 24 months to identify incident LTBI cases. Epidemiologic data, TST, T-SPOT.TB, QFT-IT and a chest X-ray were performed at baseline and after 6 months of LTBI treatment.
Thirty six percent (37/102) of patients had positive TST or Interferon Gamma Release Assays (IGRAs) tests. Agreement among TST and IGRAs was moderate (k = 0.475; p = 0.001), but high between T-SPOT.TB and QFT-IT (k = 0.785; p < 0.001). During the 24-Month follow-up, 15 (18.5%) incident cases of LTBI were identified. In comparison to TST, the IGRAs increased the LTBI diagnosis power in 8.5% (95% CI 3.16-17.49). TST-Booster did not add any value in patients with negative TST at baseline. After 6-Month isoniazid therapy, IGRAs results did not change significantly.
Almost 20% of CIA patients had some evidence of LTBI, suggesting higher conversion rate after exposition to TNFi. TST was effective in identifying new cases of LTBI, but IGRAs added diagnostic power in this scenario. Our findings did not support the repetition of IGRAs after 6-Month isoniazid therapy and this approach was effective to mitigate active TB in 2 years of follow-up.